Inflammation and Immune Activation in Antiretroviral-Treated Human Immunodeficiency Virus Type 1–Infected African Infants and Rotavirus Vaccine Responses. (7th February 2017)

• Record Type: Journal Article
• Authors: Uprety, Priyanka; Lindsey, Jane C.; Levin, Myron J.; Rainwater-Lovett, Kaitlin; Ziemniak, Carrie; Bwakura-Dangarembizix, Mutsa; Kaplan, Susan S.; Nelson, Micki; Zadzilka, Amanda; Weinberg, Adriana; Persaud, Deborah
• Is Part Of: Journal of infectious diseases. Volume 215:Number 6(2017:Mar. 15)
• Page Start: 928
• Page End: 932
• Publication Date: 2017-02-07
• Subjects: Perinatal HIV-1 infection -- antiretroviral therapy -- inflammation -- immune activation -- rotavirus vaccine.; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jix060
• Languages: English
• ISSNs: 0022-1899

Abstract

Summary: Humoral responses to pentavalent rotavirus vaccine were not impaired among perinatally human immunodeficiency virus type 1 (HIV-1)–infected infants despite elevated levels of inflammation and immune activation prior to vaccination. Abstract: Biomarkers of inflammation and immune activation were correlated with rotavirus vaccine responses in 68 human immunodeficiency virus type 1 (HIV-1)–infected (and 116 HIV-exposed but uninfected (HEU) African infants receiving pentavalent rotavirus vaccine (RV5) in a clinical trial. Prevaccination, HIV-1+ infants had significantly higher concentrations of interferon γ (IFNγ), interleukin1β, interleukin 2, interleukin 6, interleukin 10 (IL-10), and soluble CD14 compared with HEU infants. Postvaccination concentrations of neutralizing antibodies to RV5 were negatively correlated with prevaccination concentrations of IL-10 (RV5 surface proteins G1 and P1) and IFNγ (G1) in the HIV-1+ infants, whereas antirotavirus immunoglobulin A (IgA) levels were not. Heightened inflammation and immune activation in HIV-1+ infants did not alter IgA responses associated with protection from rotavirus disease. Clinical Trials Registration. 00880698